Trials / Completed
CompletedNCT01424813
A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma
A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax® Versus Placebo in Subjects 12 Years and Older With Persistent Asthma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 158 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The study will measure the change in lung function in subjects with asthma after inhaling from either of two inhalers: Albuterol Spiromax® or placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo MDPI | Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks. |
| DRUG | Albuterol MDPI | Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks. |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2013-10-01
- Completion
- 2013-11-01
- First posted
- 2011-08-29
- Last updated
- 2015-06-26
- Results posted
- 2015-05-20
Locations
38 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01424813. Inclusion in this directory is not an endorsement.